Skip to main content
Premium Trial:

Request an Annual Quote

Nick Roelofs, Victoria Blaine, Morrie Ruffin, lan Eisenberg, John Shadegg, Applera, Beckman, Bruker, ABI, Fisher, Agilent, GE Healthcare, Spotfire

People

Agilent Technologies announced this week that it has named Nick Roelofs vice president and general manager of its Life Sciences Solutions Unit. Roelofs will be responsible for product profit and loss of the business group that includes microarrays, liquid chromatographs, microfluidics, mass spectrometers, capillary electrophoresis, and informatics.

He previously served as group operations officer of Bio-Rad Laboratories’ Life Science Group. He has also served as chief operating officer of Stratagene and has held senior positions at Applied Biosystems and Baxter Diagnostics.


Victoria Blaine recently joined Qiagen as director of molecular diagnostic sales. She joined the firm from Abbott Molecular, a division of Abbott Laboratories, where she served as director of sales.


Morrie Ruffin, executive vice-president for emerging companies and business development, has left the Biotechnology Industry Organization to become CEO of consultancy LifeTech Innovations, said Jim Greenwood, president and CEO of BIO.

Ruffin will continue consulting for BIO, said Greenwood.

Alan Eisenberg, BIO's executive vice president for advocacy, operations, and communications, will assume Ruffin's responsibilities. Before joining BIO, Eisenberg served as a senior advisor on health and economics policy when Greenwood was in Congress. He was also a health policy advisor for the Senate Health, Education, Labor and Pensions Subcommittee on Public Health and a legislative assistant for Arizona's Congressman John Shadegg.

Eisenberg holds a Master of Public Policy degree from Harvard University and an MS in finance from George Washington University.

 

BioCommerce Briefs

Applera, Beckman Finalize Terms of Capillary Electrophoresis Suit

Applera and Beckman Coulter said this week that they have finalized the terms of a patent suit regarding Beckman Coulter's capillary electrophoresis technology and Applera's allegations of breach of contract.

The companies said that the terms of the agreement are "consistent" with those of a preliminary agreement that they disclosed in April (see BioCommerce Week 5/3/2006).

At the time, the companies said that Beckman would grant Applera licenses to its patents for replaceable gels for capillary electrophoresis instruments and DNA sequencers, and to its patent for a heated lid for thermal cyclers. Applera would subsequently pay Beckman $35 million to "release ... any and all claims of infringement relating to DNA sequencer and thermal cycler products."

Under the preliminary terms, Applera also agreed to grant Beckman licenses to its patents for nucleic acid sequencing and real time PCR thermalcycling for use in the diagnostics market. Consequently, Beckman would pay Applera's Celera Genomic segment $20 million over 30 months for rights to use the technology in that market.


Bruker BioSciences Completes Bruker Optics Acquisition

Bruker BioSciences said this week that it closed its acquisition of molecular spectroscopy company Bruker Optics on July 1.

The $135 million purchase price was paid approximately 59 percent in cash and 41 percent in Bruker BioSciences stock. The company said that it issued around 11.4 million new shares for the stock component of the purchase.

The number of shares was determined by dividing the value of the stock consideration, $55.8 million, by $4.91, the trailing average of Bruker closing prices per share for the period of ten consecutive trading days ending three days prior to the closing date.

Bruker BioSciences announced its plan to acquire Bruker Optics in April (see BioCommerce Week 4/19/2006).

The board of directors of Bruker Optics and the independent directors on the board of directors for Bruker BioSciences previously approved the acquisition unanimously.


ABI Licenses Fisher Unit Rights to Provide PCR Products

Applied Biosystems has granted Fisher Biosciences licenses to allow its subsidiary, Abgene, to offer several PCR and real-time PCR products, the companies said last week.

Under the agreement, Abgene will be allowed to offer PCR and real-time PCR reagents and kits, and has the right to develop new real-time PCR products and technologies, the companies said.


Agilent Signs Up Eight New Distributors for Test and Measurement Products

Agilent Technologies selected eight new distributors for its test and measurement products in Europe, the company said last week.

Under the terms of the agreements, these distributors will be the exclusive suppliers for the products in their respective regions.

The company appointed Austria's Elsinger Electronic Handel, France's Francaise d'Instrumentation-Distrame, Germany's Datatec, Switzerland's Distrelec, and the UK's FarnellInOne, a division of Premier Farnell UK. FarnellInOne will also cover all European catalog sales.

For Italy, Agilent selected Gould, Sistemi, and Pansystem. Elfa will cover Sweden, Finland, and Denmark.

The local operators will initially supply customers with Agilent's range of basic power supplies, bench digital multimeters, connectivity solutions, and the 3000 series of oscilloscopes.


GE Healthcare, Spotfire Integrate High-Content Analysis Software

Spotfire and GE Healthcare have integrated their software products into a single product for high-content analysis, the companies said last week.

Specifically, Spotfire's DecisionSite analytics software has been integrated with GE Healthcare's IN Cell Investigator software, which accompanies the IN Cell Analyzer 1000 and 3000 high-content imaging platforms.

GE Healthcare will include a customized version of DecisionSite with IN Cell Investigator "to support the standard quality control and data analysis workflows in cell-based screening," the companies said in a statement.

Financial terms were not disclosed.

The Scan

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.

Effectiveness May Decline, Data From Israel Suggests

The New York Times reports that new Israeli data suggests a decline in Pfizer-BioNTech SARS-CoV-2 vaccine effectiveness against Delta variant infection, though protection against severe disease remains high.

To See Future Risk

Slate looks into the use of polygenic risk scores in embryo screening.

PLOS Papers on Methicillin-Resistant Staphylococcus, Bone Marrow Smear Sequencing, More

In PLOS this week: genomic analysis of methicillin-resistant Staphylococcus pseudintermedius, archived bone marrow sequencing, and more.